Alternative Approach to Development of A Tb Vaccine


NIH 1998 R01 AI	Alternative Approach to Development of A Tb Vaccine Staerz, Uwe D. / National Jewish Health
NIH 1997 R01 AI	Alternative Approach to Development of A Tb Vaccine Staerz, Uwe D. / National Jewish Health
NIH 1996 R01 AI	Alternative Approach to Development of A Tb Vaccine Staerz, Uwe D. / National Jewish Health
NIH 1995 R01 AI	Alternative Approach to Development of A Tb Vaccine Staerz, Uwe D. / National Jewish Health
NIH 1994 R01 AI	Alternative Approach to Development of A Tb Vaccine Staerz, Uwe D. / National Jewish Health
NIH 1994 R01 AI	Alternative Approach to Development of A Tb Vaccine Staerz, Uwe D. / National Jewish Health
NIH 1993 R01 AI	Alternative Approach to Development of A Tb Vaccine Staerz, Uwe D. / National Jewish Health

Irion, S; Berg, R E; Staerz, U D (2000) A physiological ligand of positive selection is seen with high specificity. J Immunol 164:4601-6

Staerz, U D; Lee, D S; Qi, Y (2000) Induction of specific immune tolerance with hybrid antibodies. Immunol Today 21:172-6

Berg, R E; Irion, S; Kattman, S et al. (2000) A physiological ligand of positive selection is recognized as a weak agonist. J Immunol 165:4209-16

Berg, R E; Princiotta, M F; Irion, S et al. (1999) Positive selection of an H2-M3 restricted T cell receptor. Immunity 11:33-43

Qi, Y; Staerz, U D (1998) Specific inhibition of CD4+ T lymphocytes by a hybrid antibody. Nat Biotechnol 16:271-5

Princiotta, M F; Lenz, L L; Bevan, M J et al. (1998) H2-M3 restricted presentation of a Listeria-derived leader peptide. J Exp Med 187:1711-9

Qi, Y; Berg, R; Singleton, M A et al. (1996) Hybrid antibody mediated veto of cytotoxic T lymphocyte responses. J Exp Med 183:1973-80